Clinical trial
Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes
NCT00143520 · Daiichi Sankyo, Industry · Completed
Key facts
| NCT number | NCT00143520 |
|---|---|
| Title | Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes |
| Official title | A Randomized, Double-blind, Double-dummy, Placebo-controlled 26-week Dose-response Study of Rivoglitazone HCl (CS-011) With Active Comparator (Pioglitazone HCl) in Subjects With Type 2 Diabetes |
| Lead sponsor | Daiichi Sankyo, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes |
| Intervention type | Drug |
| Interventions | Rivoglitazone, Pioglitazone, Placebo |
| Enrollment | 441 |
| Start date | Dec 1, 2004 |
| Primary completion | Dec 1, 2005 |
| Completion | Dec 1, 2005 |
| First posted | Sep 2, 2005 |
| Last update posted | May 10, 2021 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: